Microbot Medical Inc. filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, with the Securities and Exchange Commission, disclosing continued operating losses, no revenues recognized through year-end, and 67,158,044 shares of common stock outstanding as of March 24, 2026.

Key Highlights

  • No revenues recognized: According to the filing, Microbot had not recognized any revenues through December 31, 2025, and cannot assure generating significant revenues in the future.
  • Ongoing operating losses: The company disclosed it has incurred significant operating losses since inception and expects to continue incurring significant operating losses for the foreseeable future.
  • Shares outstanding: Common stock outstanding as of March 24, 2026 totaled 67,158,044 shares.
  • Market value of non-affiliate equity: The aggregate market value of voting and non-voting common equity held by non-affiliates was approximately $95,655,000 as of the last business day of the second fiscal quarter.
  • Sole product focus: The company disclosed its business depends heavily on the success of its sole product, the LIBERTY® Endovascular Robotic Surgical System.
  • Additional funding expected: The filing states Microbot expects to need additional funding to continue its transition to a profitable commercial enterprise and build a sustainable business model.

Microbot Medical's Fiscal Year 2025 Annual Disclosure: Key Financial and Operational Details

Microbot Medical Inc. (NASDAQ:MBOT), a Delaware corporation headquartered at 175 Derby St., Bld. 27, Hingham, MA 02043, submitted its Form 10-K for the fiscal year ended December 31, 2025. The company is classified as a non-accelerated filer and a smaller reporting company, according to the filing. Microbot Israel, an Israeli corporation, is a wholly owned subsidiary of the company.

The filing identifies the LIBERTY® Endovascular Robotic Surgical System as Microbot's sole product, and states that if the company "is unable to commercialize the LIBERTY® Endovascular Robotic Surgical System, or experiences significant delays in doing so, Microbot's business will be materially harmed." The company acknowledged it ceased being primarily a research and development-stage company and has a limited operating history as a commercial-stage company, which the filing noted "may make it difficult to evaluate the prospects for the Company's future viability."

Among the principal risks summarized in the filing, the company noted that if it is unable to raise capital, it "could be forced to delay, reduce or eliminate its commercialization efforts or future product development programs." The filing also flagged reimbursement risk, stating that failure to obtain and maintain adequate third-party reimbursement for procedures involving LIBERTY® "would have a material adverse effect on Microbot's business." The filing contains forward-looking statements, which the company noted are subject to known and unknown risks and uncertainties detailed in the Risk Factors section beginning on page 13 of the report.

What Was Disclosed

Microbot Medical filed its fiscal year 2025 annual report, disclosing no revenues recognized through December 31, 2025, continued operating losses, approximately $95,655,000 in non-affiliate market equity value, and 67,158,044 shares outstanding as of March 24, 2026.